Two flow cytometric studies of hormonally treated, widely disseminated (stage D2) prostate cancer are reported in which pretreatment DNA histograms were compared with prognosis. For 29 patients studied retrospectively, no significant difference in survival was found between those with DNA diploid tumors and those having aneuploid tumors. For 37 patients studied prospectively, the median time to disease progression was estimated to be 24 months for those DNA diploid tumors and 15 months for those having aneuploid tumors. The difference in estimated time to progression did not reach statistical significance (P=0.17). For 35 of these patients, who were followed for at least 12 months after hormonal ablation, 73% of those with diploid tumors and 81% of those having aneuploid tumors had experienced disease progression by 30 months after therapy.
ASJC Scopus subject areas